Three-Fraction Intracavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen
- PMID: 30583041
- PMCID: PMC6458060
- DOI: 10.1016/j.ijrobp.2018.12.025
Three-Fraction Intracavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen
Abstract
Purpose: To report early adverse events and patient-reported outcomes (PROs) of 3-fraction intracavitary catheter-based partial breast brachytherapy (ICBB).
Materials and methods: Eligible women ≥50 years of age with ≤2.5-cm, lymph node-negative invasive or in situ breast cancer underwent breast-conserving surgery and placement of a brachytherapy applicator. ICBB was initiated on the second weekday after surgery and prescribed to 21 Gy in 3 once-daily fractions. Common Terminology Criteria for Adverse Events, version 4.0; 10-point linear analog scale assessment; the PRO version of the Common Terminology Criteria for Adverse Events; and the Harvard Breast Cosmesis Scale were used for provider and patient-reported assessments.
Results: Seventy-three women were treated for invasive (79%) or in situ (21%) breast cancer. The median time to completion of surgery and radiation therapy was 6 days. After 14-months median follow-up, 2 patients (3%) had developed breast infections that resolved with oral antibiotics. There was no other treatment-associated adverse event grade ≥2. The grade 1 seroma rate at 3 months was 20%, which dropped to 8% at 12 months; no events required intervention. At 12 months, 91% of patients reported an overall quality of life score as ≥8 of 10, and patient-reported cosmesis was good or excellent in 95%. All patients are alive without relapse at the last follow-up.
Conclusions: Three-fraction ICBB is associated with low rates of early provider and patient- reported adverse events and compares favorably with early outcomes of more protracted ICBB regimens, including twice-daily (3.4 Gy × 10) fractionation studied in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-39. Further investigation is warranted.
Copyright © 2018 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of Interests:
None.
Figures
Comment in
-
In Regard to Jethwa et al.Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1176-1177. doi: 10.1016/j.ijrobp.2019.04.018. Epub 2019 Apr 27. Int J Radiat Oncol Biol Phys. 2019. PMID: 31039419 No abstract available.
-
In Reply to Hannoun-Levi and Hannoun.Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1177-1179. doi: 10.1016/j.ijrobp.2019.04.017. Epub 2019 Apr 27. Int J Radiat Oncol Biol Phys. 2019. PMID: 31039420 Free PMC article. No abstract available.
References
-
- Correa C, et al., Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol, 2017. 7(2): p. 73–79. - PubMed
-
- Strnad V, et al., 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet, 2016. 387(10015): p. 229–38. - PubMed
-
- Livi L, et al., Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer, 2015. 51(4): p. 451–63. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
